Progress in the therapy of small cell lung cancer

Miklos Simon, Athanassios Argiris, John R. Murren

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) accounts for approximately 14% of all cases of lung cancer. Combination chemotherapy is the most effective treatment modality for SCLC and recently, several new active drugs have emerged. Combinations of platinum agents with CPT-11 or gemcitabine have been successfully compared in phase III trials against the cisplatin/etoposide standard. Modest improvements in the outcome of patients with SCLC have been noted over the last two decades. Thoracic irradiation given concurrently with chemotherapy improves survival compared with sequential chemotherapy and radiation, but this approach is associated with more toxicity. Moreover, the optimal doses and fractionation of thoracic irradiation remain to be determined. Three-dimensional treatment planning is under investigation. Prophylactic cranial irradiation (PCI) has established a role in the management of patients who have achieved a complete response to the initial therapy. Novel molecular targeted therapies are among the strategies currently being investigated in SCLC.

Original languageEnglish (US)
Pages (from-to)119-133
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume49
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
irinotecan
gemcitabine
Thorax
Molecular Targeted Therapy
Dose Fractionation
Cranial Irradiation
Drug Therapy
Etoposide
Therapeutics
Combination Drug Therapy
Platinum
Cisplatin
Lung Neoplasms
Radiation
Survival
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Prophylactic cranial irradiation
  • Radiation therapy
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Progress in the therapy of small cell lung cancer. / Simon, Miklos; Argiris, Athanassios; Murren, John R.

In: Critical Reviews in Oncology/Hematology, Vol. 49, No. 2, 02.2004, p. 119-133.

Research output: Contribution to journalArticle

Simon, Miklos ; Argiris, Athanassios ; Murren, John R. / Progress in the therapy of small cell lung cancer. In: Critical Reviews in Oncology/Hematology. 2004 ; Vol. 49, No. 2. pp. 119-133.
@article{335b06119c054a5a828a3c32aab1c113,
title = "Progress in the therapy of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) accounts for approximately 14{\%} of all cases of lung cancer. Combination chemotherapy is the most effective treatment modality for SCLC and recently, several new active drugs have emerged. Combinations of platinum agents with CPT-11 or gemcitabine have been successfully compared in phase III trials against the cisplatin/etoposide standard. Modest improvements in the outcome of patients with SCLC have been noted over the last two decades. Thoracic irradiation given concurrently with chemotherapy improves survival compared with sequential chemotherapy and radiation, but this approach is associated with more toxicity. Moreover, the optimal doses and fractionation of thoracic irradiation remain to be determined. Three-dimensional treatment planning is under investigation. Prophylactic cranial irradiation (PCI) has established a role in the management of patients who have achieved a complete response to the initial therapy. Novel molecular targeted therapies are among the strategies currently being investigated in SCLC.",
keywords = "Chemotherapy, Prophylactic cranial irradiation, Radiation therapy, Small cell lung cancer",
author = "Miklos Simon and Athanassios Argiris and Murren, {John R.}",
year = "2004",
month = "2",
doi = "10.1016/S1040-8428(03)00118-5",
language = "English (US)",
volume = "49",
pages = "119--133",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Progress in the therapy of small cell lung cancer

AU - Simon, Miklos

AU - Argiris, Athanassios

AU - Murren, John R.

PY - 2004/2

Y1 - 2004/2

N2 - Small cell lung cancer (SCLC) accounts for approximately 14% of all cases of lung cancer. Combination chemotherapy is the most effective treatment modality for SCLC and recently, several new active drugs have emerged. Combinations of platinum agents with CPT-11 or gemcitabine have been successfully compared in phase III trials against the cisplatin/etoposide standard. Modest improvements in the outcome of patients with SCLC have been noted over the last two decades. Thoracic irradiation given concurrently with chemotherapy improves survival compared with sequential chemotherapy and radiation, but this approach is associated with more toxicity. Moreover, the optimal doses and fractionation of thoracic irradiation remain to be determined. Three-dimensional treatment planning is under investigation. Prophylactic cranial irradiation (PCI) has established a role in the management of patients who have achieved a complete response to the initial therapy. Novel molecular targeted therapies are among the strategies currently being investigated in SCLC.

AB - Small cell lung cancer (SCLC) accounts for approximately 14% of all cases of lung cancer. Combination chemotherapy is the most effective treatment modality for SCLC and recently, several new active drugs have emerged. Combinations of platinum agents with CPT-11 or gemcitabine have been successfully compared in phase III trials against the cisplatin/etoposide standard. Modest improvements in the outcome of patients with SCLC have been noted over the last two decades. Thoracic irradiation given concurrently with chemotherapy improves survival compared with sequential chemotherapy and radiation, but this approach is associated with more toxicity. Moreover, the optimal doses and fractionation of thoracic irradiation remain to be determined. Three-dimensional treatment planning is under investigation. Prophylactic cranial irradiation (PCI) has established a role in the management of patients who have achieved a complete response to the initial therapy. Novel molecular targeted therapies are among the strategies currently being investigated in SCLC.

KW - Chemotherapy

KW - Prophylactic cranial irradiation

KW - Radiation therapy

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0842263747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842263747&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00118-5

DO - 10.1016/S1040-8428(03)00118-5

M3 - Article

C2 - 15012973

AN - SCOPUS:0842263747

VL - 49

SP - 119

EP - 133

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -